JWH-171

JWH-171 is a synthetic cannabinoid from the JWH series. It was developed by the team led by John W. Huffman, an organic chemist at Clemson University. JWH-171 is part of a series of alkylated naphthoylindoles, which are known for their potent cannabinoid receptor agonist properties.

History

The JWH series was developed in the mid-1990s by Huffman and his team in an effort to create a new class of cannabinoids. The series is named after Huffman's initials. JWH-171 is one of the many compounds in this series.

Chemistry

JWH-171 is a synthetic cannabinoid, which means it is a chemical compound designed to mimic the effects of natural cannabinoids. It is an alkylated naphthoylindole, a type of compound known for its potent cannabinoid receptor agonist properties. The chemical structure of JWH-171 allows it to bind to the cannabinoid receptors in the body, producing effects similar to those of natural cannabinoids.

Pharmacology

As a synthetic cannabinoid, JWH-171 acts as an agonist at the CB1 receptor and CB2 receptor, the two main cannabinoid receptors in the body. This means it can produce a range of effects, including pain relief, relaxation, and altered perception. However, because it is a synthetic compound, it may also produce unwanted side effects, and its use is associated with a number of health risks.

Legal Status

The legal status of JWH-171 varies by country. In many places, it is considered a controlled substance due to its potential for abuse and the health risks associated with its use. In the United States, for example, it is classified as a Schedule I controlled substance, which means it is illegal to manufacture, distribute, or possess without a license.

See Also

• JWH series
• Synthetic cannabinoids
• Cannabinoid receptor

‎

‎